دورية أكاديمية
Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.
| العنوان: | Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. |
|---|---|
| المؤلفون: | Buege MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kumar A; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dixon BN; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tang LA; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pak T; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Orozco J; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Peterson TJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Maples KT; Memorial Sloan Kettering Cancer Center, New York, NY, USA. |
| المصدر: | The Annals of pharmacotherapy [Ann Pharmacother] 2020 Sep; Vol. 54 (9), pp. 879-898. Date of Electronic Publication: 2020 Feb 20. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sage Country of Publication: United States NLM ID: 9203131 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-6270 (Electronic) Linking ISSN: 10600280 NLM ISO Abbreviation: Ann Pharmacother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Sept. 2013- : Thousand Oaks, CA : Sage Original Publication: Cincinnati, OH : Harvey Whitney Books Co., c1992- |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation*, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Lymphoma, Mantle-Cell/*drug therapy, Administration, Oral ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Treatment Outcome |
| مستخلص: | Objectives: To discuss (1) recent and emerging data for pharmacological management of untreated and relapsed/refractory (R/R) mantle cell lymphoma (MCL) with agents approved in the United States, (2) important considerations for toxicity monitoring and management, and (3) preliminary data and ongoing studies for agents in MCL-specific clinical trials. Data Sources: PubMed/MEDLINE, EMBASE, Google Scholar, product labeling, National Comprehensive Cancer Network, American Cancer Society, and ClinicalTrials.gov were searched for studies published between January 1, 2017, and January 31, 2020, and key historical trials. Study Selection and Data Extraction: Relevant studies conducted in humans and selected supporting preclinical data were reviewed. Data Synthesis: MCL is a rare but usually aggressive non-Hodgkin lymphoma that most commonly affects the older population. Traditionally, the treatment of MCL has been determined based on transplant eligibility. Newer data suggest that more tolerable frontline therapy may produce outcomes similar to intensive historical induction regimens, possibly precluding fewer patients from autologous stem cell transplant and producing better long-term outcomes in transplant-ineligible patients. In the R/R setting, novel regimens are improving outcomes and changing the landscape of treatment. Relevance to Patient Care and Clinical Practice: This review summarizes and discusses recent and emerging data for management of newly diagnosed and R/R MCL; key supportive care considerations for agents are also discussed. Conclusions: Recent study results are changing management of MCL. Although these data have complicated the picture of regimen selection, increasingly effective and tolerable therapy and additional anticipated data point to a brighter future for patients with MCL. |
| References: | Leukemia. 2018 Aug;32(8):1799-1803. (PMID: 29572505) J Natl Cancer Inst. 2007 May 2;99(9):706-14. (PMID: 17470738) Hematol Oncol. 2018 Oct;36(4):624-632. (PMID: 29512173) Br J Haematol. 2016 Nov;175(3):410-418. (PMID: 27378674) Cancer Med. 2019 Nov;8(16):6860-6870. (PMID: 31560165) N Engl J Med. 2015 Mar 5;372(10):944-53. (PMID: 25738670) Ann Oncol. 2013 Jun;24(6):1587-93. (PMID: 23504948) N Engl J Med. 2016 Jan 28;374(4):311-22. (PMID: 26639348) Leuk Lymphoma. 2010 Mar;51(3):406-14. (PMID: 20038221) Br J Haematol. 2012 Feb;156(3):346-53. (PMID: 22145911) Lancet. 2016 Feb 20;387(10020):770-8. (PMID: 26673811) Leuk Lymphoma. 2018 Feb;59(2):311-320. (PMID: 28629235) Nat Rev Cancer. 2018 Mar;18(3):148-167. (PMID: 29348577) Blood. 2016 Jan 28;127(4):411-9. (PMID: 26542378) Oncotarget. 2016 Sep 6;7(36):58638-58648. (PMID: 27449094) Support Care Cancer. 2013 Sep;21(9):2437-42. (PMID: 23591714) Leuk Lymphoma. 2019 Jan;60(1):172-179. (PMID: 28583031) J Clin Oncol. 2005 Oct 1;23(28):7013-23. (PMID: 16145068) Am J Hematol. 2018 Jan;93(1):E1-E3. (PMID: 28960532) Nat Med. 2013 Feb;19(2):202-8. (PMID: 23291630) J Clin Oncol. 2009 Feb 1;27(4):511-8. (PMID: 19075279) N Engl J Med. 2018 Mar 29;378(13):1211-1223. (PMID: 29590547) Blood. 2012 May 17;119(20):4597-607. (PMID: 22383795) Arch Intern Med. 1996 Jan 22;156(2):177-88. (PMID: 8546551) Leuk Lymphoma. 2017 Jul;58(7):1530-1537. (PMID: 27894215) N Engl J Med. 2013 Aug 8;369(6):507-16. (PMID: 23782157) Trends Cancer. 2018 Mar;4(3):197-206. (PMID: 29506670) Br J Haematol. 2013 Feb;160(4):487-502. (PMID: 23252516) Leukemia. 2021 Nov;35(11):3201-3211. (PMID: 33907299) Br J Haematol. 2019 Feb;184(3):460-462. (PMID: 29527676) Blood. 2008 Oct 1;112(7):2687-93. (PMID: 18625886) Leuk Lymphoma. 2011 Aug;52(8):1488-94. (PMID: 21623691) Br J Haematol. 2018 May;181(4):561-564. (PMID: 28369820) Leuk Lymphoma. 2019 Mar;60(3):748-755. (PMID: 30188225) Am J Hematol. 2019 May;94(S1):S3-S9. (PMID: 30680780) Oncotarget. 2017 Nov 03;8(68):112516-112529. (PMID: 29348844) Eur J Haematol. 2003 Aug;71(2):73-80. (PMID: 12890145) Biol Blood Marrow Transplant. 2017 Aug;23(8):1264-1268. (PMID: 28434928) Lancet Oncol. 2011 May;12(5):431-40. (PMID: 21507715) Blood Cancer J. 2015 Oct 23;5:e362. (PMID: 26495859) Cancer. 2008 Aug 15;113(4):791-8. (PMID: 18615506) Blood. 2019 Mar 14;133(11):1201-1204. (PMID: 30692121) Clin Cancer Res. 2016 Apr 15;22(8):2000-8. (PMID: 26631614) Clin Infect Dis. 2019 Jan 7;68(2):247-255. (PMID: 29800121) Cancer. 2003 Dec 15;98(12):2630-5. (PMID: 14669282) J Clin Oncol. 2019 Apr 20;37(12):984-991. (PMID: 30811293) N Engl J Med. 2017 Sep 28;377(13):1250-1260. (PMID: 28953447) Leuk Lymphoma. 2024 Feb;65(2):235-241. (PMID: 38264906) Blood. 2016 Oct 6;128(14):1814-1820. (PMID: 27354719) Br J Haematol. 2014 Mar;164(6):811-21. (PMID: 24328678) J Clin Oncol. 2017 Mar 10;35(8):826-833. (PMID: 28095146) Blood. 1997 Jun 1;89(11):3909-18. (PMID: 9166827) Blood Cancer J. 2019 May 20;9(6):50. (PMID: 31110172) Exp Hematol. 2017 May;49:34-38.e2. (PMID: 28115200) Blood. 2014 Mar 13;123(11):1665-73. (PMID: 24458437) Blood. 2014 Oct 9;124(15):2467-8. (PMID: 25301337) Leukemia. 2019 Nov;33(11):2762-2766. (PMID: 31558766) Clin Cancer Res. 2016 Apr 1;22(7):1572-82. (PMID: 26660519) Br J Haematol. 2017 Nov;179(3):399-409. (PMID: 28771673) Am J Hematol. 2019 Feb;94(2):E50-E53. (PMID: 30474171) Blood. 2019 Feb 28;133(9):940-951. (PMID: 30538135) Blood. 2018 Dec 27;132(26):2722-2729. (PMID: 30385481) Leukemia. 2011 Dec;25(12):1904-8. (PMID: 21720382) Haematologica. 2017 May;102(5):e203-e206. (PMID: 28082342) Br J Haematol. 2019 Sep;186(6):845-854. (PMID: 31177537) Blood. 2010 Apr 22;115(16):3416-7. (PMID: 20413666) J Clin Oncol. 1998 Dec;16(12):3803-9. (PMID: 9850025) N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490) Lancet. 2013 Apr 6;381(9873):1203-10. (PMID: 23433739) N Engl J Med. 2016 Feb 25;374(8):792-3. (PMID: 26933863) Blood. 2014 Dec 18;124(26):3991-5. (PMID: 25305202) Leuk Lymphoma. 2018 Dec;59(12):2792-2800. (PMID: 29764250) Leuk Lymphoma. 2015;56(11):3216-8. (PMID: 25760636) Leukemia. 2020 May;34(5):1458-1461. (PMID: 31827243) Blood. 2014 May 8;123(19):2944-52. (PMID: 24591201) Br J Haematol. 2004 Oct;127(1):3-11. (PMID: 15384972) Leuk Lymphoma. 2019 Aug;60(8):1853-1865. (PMID: 30696305) Lancet Oncol. 2018 Nov;19(11):1449-1458. (PMID: 30348538) Blood Adv. 2019 Oct 22;3(20):3132-3135. (PMID: 31648328) Am J Hematol. 2021 Jun 1;96(6):680-689. (PMID: 33735476) Ann Hematol. 2014 Nov;93(11):1879-87. (PMID: 24951124) Lancet Oncol. 2012 Jul;13(7):716-23. (PMID: 22677155) Blood. 2006 May 1;107(9):3575-83. (PMID: 16282346) Blood. 2018 Nov 8;132(19):2016-2025. (PMID: 30181173) Leukemia. 2014 Feb;28(2):407-10. (PMID: 23979520) Oncologist. 2013;18(8):954-64. (PMID: 23900001) Clin Infect Dis. 2018 Aug 16;67(5):687-692. (PMID: 29509845) Leuk Lymphoma. 2019 Dec;60(12):2917-2921. (PMID: 31120355) Lancet. 2016 Aug 6;388(10044):565-75. (PMID: 27313086) Lancet Oncol. 2016 Jan;17(1):48-56. (PMID: 26640039) Haematologica. 2020 Jan 31;105(2):e76-e79. (PMID: 31171645) Oncogene. 2016 Dec 1;35(48):6223-6234. (PMID: 27157620) Br J Haematol. 2015 Mar;168(5):765-8. (PMID: 25284608) Blood. 2006 Mar 1;107(5):1800-5. (PMID: 16282339) Lancet Haematol. 2018 Mar;5(3):e109-e116. (PMID: 29396091) Blood. 2013 Oct 3;122(14):2412-24. (PMID: 23940282) Clin Infect Dis. 2018 Jan 6;66(1):140-148. (PMID: 29029010) Cancer Discov. 2014 Sep;4(9):1022-35. (PMID: 25082755) Br J Haematol. 2017 Mar;176(5):759-769. (PMID: 27992063) Br J Haematol. 2016 Apr;173(1):89-95. (PMID: 26729345) Blood. 1994 Oct 15;84(8):2726-32. (PMID: 7919385) Leuk Lymphoma. 2020 Feb;61(2):364-369. (PMID: 31603363) N Engl J Med. 2015 Nov 5;373(19):1835-44. (PMID: 26535512) Blood Adv. 2018 Jun 26;2(12):1429-1438. (PMID: 29934343) Lancet Haematol. 2017 Jan;4(1):e15-e23. (PMID: 27927586) Leuk Lymphoma. 2018 Oct;59(10):2465-2469. (PMID: 29390929) Br J Haematol. 2016 Jan;172(1):80-8. (PMID: 26648336) Hematol Oncol. 2017 Dec;35(4):424-431. (PMID: 27734524) J Clin Oncol. 2020 Jan 20;38(3):248-256. (PMID: 31804876) Clin Cancer Res. 2014 Nov 1;20(21):5365-71. (PMID: 25361916) Blood Cancer J. 2017 Nov 23;7(12):631. (PMID: 29167420) Haematologica. 2017 Jul;102(7):1133-1136. (PMID: 28655809) Blood. 2010 Aug 19;116(7):1025-34. (PMID: 20427703) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: bone marrow transplantation; clinical pharmacy; hematology; lymphoma; oncology |
| تواريخ الأحداث: | Date Created: 20200222 Date Completed: 20201113 Latest Revision: 20240407 |
| رمز التحديث: | 20240407 |
| مُعرف محوري في PubMed: | PMC8330616 |
| DOI: | 10.1177/1060028020909117 |
| PMID: | 32079411 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1542-6270 |
|---|---|
| DOI: | 10.1177/1060028020909117 |